UNITED FOOD & COMMERCIAL WORKERS CENTRAL PENNSYLVANIA & REGIONAL HEALTH & WELFARE FUND, et al., Plaintiffs-Appellants, v. AMGEN, INC., Defendant-Appellee.
No. 09-56118
United States Court of Appeals, Ninth Circuit
Argued and Submitted Oct. 8, 2010. Filed Oct. 21, 2010.
255-258
The District Court found that both recommendations are rooted in the Proxy Statement itself, which is encompassed by the Settlement Agreement. We agree. Because the Pay for Performance recommendation was part of the Proxy Statement and the Proxy Statement is encompassed by the Settlement Agreement, all claims arising out of the Proxy Statement are barred by the Settlement Agreement.
Finally, the District Court denied CBA leave to amend its complaint because the court viewed any attempt to cure the complaint‘s deficiencies to be futile. CBA highlights this court‘s strong policy favoring amendments of pleadings, Bowles, 198 F.3d at 757, but does not identify any plausible facts which could be alleged to save its claims. Because it is not clear what facts could be alleged to cure CBA‘s complaint deficiencies and CBA suggests none, the District Court did not abuse its discretion in denying leave to amend.
AFFIRMED.
Brandon M. Anderson, Esquire, Joseph M. Burns, Esquire, Jacobs Burns Orlove Stanton & Hernandez, Ben Barnow, Esquire, Barnow and Associates, P.C., Marvin A. Miller, Miller Law LLC, Chicago, IL, Timothy J. Becker, Esquire, Zimmer-
Sheila S. Brinbaum, Esquire, Mark Cheffo, Barbara Wrubel, James Russell Jackson, Esquire, Akadden, Arps, Slate, Meagher and Flom, New York, NY, Ronni Fuchs, Dechert LLP, Princeton, NJ, Darrel J. Hieber, Esquire, Skadden, Arps, Slate, Meagher & Flom LLP, Los Angeles, CA, Robert Limbacher, Will W. Sachse, Dechert LLP, Philadelphia, PA, for Defendant-Appellee.
Before: PREGERSON, D.W. NELSON and IKUTA, Circuit Judges.
MEMORANDUM*
Appellants’ complaint cannot survive a motion to dismiss because it failed to plead its allegations of fraud under RICO,
Moreover, the complaint failed to plead a cognizable theory of proximate causation that links Amgen‘s alleged misconduct to Appellants’ alleged injury. Bridge v. Phoenix Bond & Indem. Co., 553 U.S. 639, 654-55, 128 S.Ct. 2131, 170 L.Ed.2d 1012 (2008). Instead, the complaint proffered an attenuated causal chain that involved at least four independent links, namely, (1) the USP-DI‘s listing of Aranesp for anemia of cancer, (2) Medicare‘s decision to cover Aranesp for anemia of cancer, (3) third-party payors’ decision to cover Aranesp for anemia of cancer (in addition to covering Aranesp for anemia in heart failure patients and cancer directly, and Epogen for all of these uses), and (4) doctors’ decisions to prescribe Aranesp and Epogen for these uses. This causal theory is too attenuated to satisfy the Supreme Court‘s proximate causation requirement in the RICO context. See Hemi Group, LLC v. City of New York, — U.S. —, —, 130 S.Ct. 983, 989, 175 L.Ed.2d 943 (2010) (quoting Holmes v. Sec. Investor Prot. Corp., 503 U.S. 258, 268, 271, 274, 112 S.Ct. 1311, 117 L.Ed.2d 532 (1992)).
The complaint also failed to satisfy Rule 9(b) with respect to its UCL claims, Kearns, 567 F.3d at 1125, because it did not explain why Amgen‘s conduct was fraudulent, id., or allege an adequate theory of causation or reliance. In re Tobacco II Cases, 46 Cal.4th 298, 306, 93 Cal. Rptr.3d 559, 207 P.3d 20 (2009); see also Hall v. Time Inc., 158 Cal.App.4th 847, 855-56 & nn. 2-3, 70 Cal.Rptr.3d 466 (Ct. App.2008). Because the complaint sounded in fraud, all of its allegations are subject to
AFFIRMED.
